Knowledge-Based Virtual Screening: Application to the MDM4/p53 Protein–Protein Interaction-Reference-Cited by-同舟云学术

Knowledge-Based Virtual Screening: Application to the MDM4/p53 Protein–Protein Interaction

Published:2009 Issue: Volume: Page:173-194
ISSN:1064-3745
Container-title:Methods in Molecular Biology
language:
Short-container-title:

Author:

Jacoby Edgar,Boettcher Andreas,Mayr Lorenz M.,Brown Nathan,Jenkins Jeremy L.,Kallen Joerg,Engeloch Caroline,Schopfer Ulrich,Furet Pascal,Masuya Keiichi,Lisztwan Joanna

Publisher

Humana Press

Link

http://link.springer.com/content/pdf/10.1007/978-1-60761-274-2_7.pdf

Reference63 articles.

1. Caron, P.R., Mullican, M.D., Mashal, R.D., Wilson, K.P., Su, M.S., and Murcko, M.A. (2001) Chemogenomic approaches to drug discovery. Curr. Opin. Chem. Biol. 5, 464–470.

2. Mestres, J. (2004) Computational chemogenomics approaches to systematic knowledge-based drug discovery. Curr. Opin. Drug Discov. Devel. 7, 304–314.

3. Kubini, H., and Müller, G. (eds.) (2004) Chemogenomics in Drug Discovery – A Medicinal Chemistry Perspective. Wiley-VCH, Weinheim.

4. Jacoby, E. (2006) Chemogenomics: drug discovery’s panacea? Mol. Biosyst. 2, 218–220.

5. Jacoby, E. (ed.) (2006) Chemogenomics – Knowledge-Based Approaches to Drug Discovery. Imperial College Press, London.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes;ChemMedChem;2019-05-27

2. Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs;CHIMIA;2017-10-25

3. An Effective Virtual Screening Protocol To Identify Promising p53–MDM2 Inhibitors;Journal of Chemical Information and Modeling;2016-06-07

4. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53–MDM2 interaction with a distinct binding mode;Bioorganic & Medicinal Chemistry Letters;2015-09

5. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors;Journal of Medicinal Chemistry;2015-08-05